Results 101 to 110 of about 3,757,122 (344)

History of evidence-based medicine

open access: yesIndian Journal of Urology, 2011
This essay reviews the historical circumstances surrounding the introduction and evolution of evidence-based medicine. Criticisms of the approach are also considered.
Roger L Sur, Philipp Dahm
doaj   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

History matters...through partnerships that advance research, education, and public service

open access: yesJournal of the Medical Library Association, 2017
The article deals with the ongoing strategic partnership between the History of Medicine Division at the National Library of Medicine and Virginia Polytechnic Institute and State University (Virginia Tech) to allow researchers, educators, and students ...
Jeffrey S. Reznick, E. Thomas Ewing
doaj   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias   +12 more
wiley   +1 more source

Recycling the evidence: different approaches to the reanalysis of gerontological data [PDF]

open access: yes, 2005
In 1991 Professor Margot JEFFERYS and two colleagues interviewed "pioneers of geriatric medicine" of whom 60 were geriatricians. These data are now on disk and can be searched digitally. The interviews were long and focussed on the careers of the doctors
Bornat, Joanna
core   +2 more sources

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Home - About - Disclaimer - Privacy